Ottawa, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The global mRNA synthesis & manufacturing market size is calculated at USD 1.55 billion in 2024, grows to USD 1.58 billion in 2025, and is projected to hit ...

The global mRNA synthesis and manufacturing market is projected to grow at a compound annual growth rate of approximately 6% during the forecast period, reflecting the expanding role of mRNA ...

(MENAFN- GlobeNewsWire - Nasdaq) The mRNA Therapeutics CDMO market sees opportunities in scaling mRNA production due to increased demand for mRNA-based drugs and vaccines. Innovations in manufacturing ...

mRNAワクチン製造プロセス開発に適した高品質の酵素を発売 タカラバイオ株式会社は、mRNAワクチン製造におけるプロセス開発に適したHigh Quality（HQ）グレード（注1）のmRNA製造用酵素「Pyrophosphatase (inorganic),HQ」を8月31日より新発売します。 「Pyrophosphatase ...

According to SNS Insider, the global mRNA synthesis raw material market was valued at USD 1.70 billion in 2024 and is projected to reach USD 2.67 billion by 2032, at a compound annual growth rate ...

A graduate student from the Massachusetts Institute of Technology (MIT) is poised to commercialize a new technology for improving the cost-effectiveness of mRNA manufacture. Nathan Stover is working ...

mRNAワクチン製造プロセス開発に最適な不純物生成を抑制した独自のRNA合成酵素のHigh Qualityグレード品を発売 タカラバイオ株式会社は、mRNAワクチン製造におけるプロセス開発に適したHigh QualityグレードのmRNA製造用酵素「PrimeCap(TM) T7 RNA Polymerase (low dsRNA), HQ ...

Advanced analytics and artificial intelligence (AI) will help make mRNA vaccines and therapeutics better by allowing biopharma engineers to fine-tune the enzymes used to manufacture such products.

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The ...

“There is growing recognition across the industry that LNP manufacturing challenges are not solely scientific, but are also largely operational in nature,” said Dr. Blerina Shkodra, lead author of the ...

アクセリード株式会社（代表取締役社長：藤澤朋行／以下、アクセリード）は、合弁会社「株式会社ARCALIS」（代表取締役社長：藤澤朋行／以下、アルカリス）をArcturus Therapeutics Holdings, Inc.（President & CEO：Joseph E. Payne, NASDAQ：ARCT／以下、アークトゥルス）と ...

Thailand’s Department of Medical Sciences says online claims that mRNA vaccines contain SV40 and raise cancer risk are false, citing the modern manufacturing process and strict quality controls.